DeBakey High School for Health Professions is at the top of the class. Photo by skynesher/Getty Images

Three Houston high schools deserve a tip of the cap (or mortarboard) after earning marks for excellence. On June 12, U.S. News & World Report released its annual Best U.S. High Schools by metro area, ranking the top public schools in each major city.

DeBakey High School for Health Professions is at the top of the class in the Bayou City. In addition to earning top marks for academics, the school is notably comprised of mostly minority students — 89 percent.

To determine the country's best schools, U.S. News ranked each school using six metrics, applying different weights to each category:

  • College readiness (30 percent)
  • Math and reading proficiency (20 percent)
  • Math and reading performance (20 percent)
  • Underserved service (10 percent)
  • College curriculum breadth (10 percent)
  • Graduation rate (10 percent)

Based on the above, the school has an overall score of 99.9 (or an A-plus in high school lingo), complete with 100 percent graduation and reading and mathematics proficiency rates. Also, 100 percent of students took and passed at least one AP exam.

Located on the prestigious Texas Medical Center Campus, DeBakey offers students unparalleled access to on-site research facilities, as well as future academic opportunities, U.S. News notes.

"Graduates are eligible for the Houston Premedical Academy, an undergraduate program at the University of Houston designed specifically for DeBakey High School students," the report says. "Those selected for the premedical academy receive provisional acceptance to the Baylor College of Medicine."

DeBakey ranks first in Houston and No. 17 nationally. The school is also rated No. 10 in the U.S. among magnet schools and No. 11 among STEM schools.

Carnegie Vanguard High School earned the No. 2 spot in Houston, 24th in the nation, followed by Eastwood Academy at No. 3 locally and 97th nationally.

---

A version of this story, with information on Texas' other metros, originally was published on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”